Search

Your search keyword '"Clerico, M."' showing total 456 results
Start Over Author "Clerico, M."
456 results on '"Clerico, M."'

52. Extended interval dosing of natalizumab: is efficacy preserved?

Author

Clerico, M., Signori, A., Mercanti, S., Cordioli, C., Signoriello, E., Lus, G., Maniscalco, G. T., Curti, E., Lorefice, L., Cocco, E., Nociti, V., Mirabella, M., Baroncini, D., Landi, D., Mataluni, G., Petruzzo, M., Lanzillo, R., Gandoglia, I., Laroni, A., RITA FRANGIAMORE, Sartori, A., Cavalla, P., Costantini, G., Sormani, M. P., and Capra, R.

Published
2018

58. Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group

Author

Signori, A, Sormani, Mp, Maniscalco, Gt, Signoriello, E, Rossi, S, Gutierrez, Lp, Sacca, F, Russo, Cv, Lo Fermo, S, Repice, Am, Baroncini, D, Annovazzi, P, Clerico, M, Cerqua, R, Binello, E, Mataluni, G, Frau, J, Cocco, E, Zarbo, R, Laroni, A, Sartori, A, Cordioli, C, Rasia, S, Bonavita, S, Lavorgna, L, Esposito, S, Clerici, Valt, La Gioia, S, Frigeni, B, Barcella, V, Pontecorvo, S, Di Sapio, A, Grasso, R, Stromillo, Ml, Barrila, C, Gallo, F, and Lanzillo, R

Published
2017

61. Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram

Author

Fornaro, L., primary, Parnofiello, A., additional, Ugolini, C., additional, Cardarelli, N., additional, De Maglio, G., additional, Pecora, I., additional, Crivelli, F., additional, Catanese, S., additional, Cardellino, G., additional, Musettini, G., additional, Pella, N., additional, Pasquini, G., additional, Pizzolitto, S., additional, Salani, F., additional, Clerico, M., additional, Fontanini, G., additional, Fasola, G., additional, Maurizio, D., additional, Vivaldi, C., additional, and Montagnani, F., additional

Published
2018
Full Text
View/download PDF

81. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Author

Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A, Bridge Study Group, Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A, Bridge Study Group, Lugaresi, A, Florio, C, BRESCIA MORRA, Vincenzo, Cottone, S, Bellantonio, P, Clerico, M, Centonze, D, Uccelli, A, di Ioia, M, De Luca, G, Marcellusi, A, Paolillo, A, and for the BRIDGE study, Group

Subjects
Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Injections, Subcutaneous, Population, Clinical Neurology, Self Administration, Hospital Anxiety and Depression Scale, lcsh:RC346-429, IFN beta, Disability Evaluation, Young Adult, Autoinjector, Internal medicine, medicine, Humans, Immunologic Factors, multiple sclerosis, autoinjector, device, electronic, adherence, tolerability, Adverse effect, education, Medication adherence, lcsh:Neurology. Diseases of the nervous system, Pain Measurement, education.field_of_study, Analysis of Variance, Expanded Disability Status Scale, business.industry, General Medicine, Interferon-beta, Middle Aged, Drug delivery systems, Clinical trial, Logistic Models, Treatment Outcome, Tolerability, Physical therapy, Anxiety, Patient Compliance, Relapsing-remitting multiple sclerosis, Female, Settore MED/26 - Neurologia, Neurology (clinical), medicine.symptom, business, Research Article, Follow-Up Studies
Abstract

Background Achieving good adherence to self-injected treatments for multiple sclerosis can be difficult. Injection devices may help to overcome some of the injection-related barriers to adherence that can be experienced by patients. We sought to assess short-term adherence to, and tolerability of, interferon (IFN) β-1a administered via electronic autoinjection device in patients with relapsing-remitting multiple sclerosis (RRMS). Methods BRIDGE (RebiSmart to self-inject Rebif serum-free formulation in a multidose cartridge) was a 12-week, multicentre, open-label, single-arm, observational, Phase IV study in which patients self-administered IFN β-1a (titrated to 44 μg), subcutaneously (sc), three times weekly, via electronic autoinjection device. Patients were assessed at baseline and 4-weekly intervals to Week 12 or early termination (ET) for: physical examinations; diary card completion (baseline, Weeks 4, 8 only); neurological examinations (baseline, Week 12/ET only); MS Treatment Concern Questionnaire (MSTCQ; Weeks 4, 8, 12 only); Convenience Questionnaire (Week 12 only); Hospital Anxiety and Depression Scale (HADS); and Paced Auditory Serial Addition Task (PASAT; baseline only). Adherence was defined as administration of ≥ 80% of scheduled injections, recorded by the autoinjection device. Results Overall, 88.2% (105/119; intent-to-treat population) of patients were adherent; 67.2% (80/119) administered all scheduled injections. Medical reasons accounted for 35.6% (31/87) of missed injections, forgetfulness for 20.6% (18/87). Adherence did not correlate with baseline Expanded Disability Status Scale (P = 0.821) or PASAT (P = 0.952) scores, or pre-study therapy (P = 0.303). No significant changes (baseline-Week 12) in mean HADS depression (P = 0.482) or anxiety (P = 0.156) scores were observed. 'Overall convenience' was the most important reported benefit of the autoinjection device. Device features associated with handling and ease of use were highly rated. Mean MSTCQ scores for 'flu-like' symptoms (P = 0.022) and global side effects (P = 0.002) significantly improved from Week 4-12. Mean MSTCQ scores for pain at injection site and injection pain increased from Week 4-12 (P < 0.001). Adverse events were mild/moderate. No new safety signals were identified. Conclusion Convenience and ease of use of the autoinjection device may improve adherence and, therefore, outcomes, in patients with RRMS receiving sc IFN β-1a. Trial registration EU Clinical Trials Register (EU-CTR; http://www.clinicaltrialsregister.eu): 2009-013333-24

Published
2012

82. CNS RELAPSE OF DIFFUSE LARGE B‐CELL LYMPHOMA AND ROLE OF UPFRONT PROPHYLAXIS: A 10‐YEAR SINGLE CENTER EXPERIENCE.

Author

Savelli, C. Benevolo, Novo, M., Fasano, F., Evangelista, A., Cavallo, F., Boccomini, C., Orsucci, L., Clerico, M., Peri, V., Bruno, B., Botto, B., and Freilone, R.

Subjects
DIFFUSE large B-cell lymphomas, PREVENTIVE medicine
Abstract

In univariate analysis CNS relapse risk was significantly influenced by ECOG PS and elevated LDH levels, while the use of prophylaxis was not shown to impact the risk of CNS recurrence. 95/397 pts received CNS prophylaxis (24%): 59 by intrathecal (IT) route only (15%) ( I n i 26 CNS-IPI 2-3; I n i 29 CNS-IPI 4-6), 25 by iv MTX only (6%) ( I n i 17 HD-MTX >=3 g/mq; n 6 CNS-IPI 2-3; I n i 16 CNS-IPI 4-6), and 11 by combined route (3%) ( I n i 5 CNS-IPI 2-3, I n i 6 CNS-IPI 3-6). 12 pts experienced CNS relapse; 8/12 exclusively CNS and 4/12 along with systemic recurrence. B Introduction: b Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a rare event, occurring in about 5% of patients (pts) and correlating with a very dismal prognosis. [Extracted from the article]

Published
2023
Full Text
View/download PDF

83. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

Author

Landi, D, De Rossi, N, Zagaglia, S, Scarpazza, C, Prosperini, L, Albanese, M, Buttari, F, Mori, F, Marfia, G, Sormani, M, Capra, R, Centonze, D, Amato, M, Bandini, F, Bertolotto, A, Brescia Morra, V, Cavaletti, G, Cavalla, P, Capobianco, M, Clerico, M, D'Aleo, G, de Riz, M, Deotto, L, Durelli, L, Falcini, M, Ferrari, E, Fusco, M, Gasperini, C, Gerevini, S, Ghezzi, A, Grimaldi, L, Guidotti, M, Lugaresi, A, Naldi, P, Moiola, L, Perrone, P, Pizzorno, M, Pozzilli, C, Rezzonico, M, Rovaris, M, Salemi, G, Salvetti, M, Santuccio, G, Scarpini, E, Sessa, E, Solaro, C, Tabiadon, G, Tortorella, C, Trojano, M, Amato, MP, Fusco, ML, Trojano, M., CAVALETTI, GUIDO ANGELO, Landi, D, De Rossi, N, Zagaglia, S, Scarpazza, C, Prosperini, L, Albanese, M, Buttari, F, Mori, F, Marfia, G, Sormani, M, Capra, R, Centonze, D, Amato, M, Bandini, F, Bertolotto, A, Brescia Morra, V, Cavaletti, G, Cavalla, P, Capobianco, M, Clerico, M, D'Aleo, G, de Riz, M, Deotto, L, Durelli, L, Falcini, M, Ferrari, E, Fusco, M, Gasperini, C, Gerevini, S, Ghezzi, A, Grimaldi, L, Guidotti, M, Lugaresi, A, Naldi, P, Moiola, L, Perrone, P, Pizzorno, M, Pozzilli, C, Rezzonico, M, Rovaris, M, Salemi, G, Salvetti, M, Santuccio, G, Scarpini, E, Sessa, E, Solaro, C, Tabiadon, G, Tortorella, C, Trojano, M, Amato, MP, Fusco, ML, Trojano, M., and CAVALETTI, GUIDO ANGELO

Abstract

Objective: To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)-associated progressive multifocal leukoencephalopathy (PML).Methods: The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients' clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior immunosuppressant exposure, PML symptoms, PML lesion location at diagnosis, CSF JC virus status and copies, additional PML treatments and steroids, and PML immune reconstitution inflammatory syndrome ( IRIS) development were investigated with both univariate and multivariate analyses.Results: A total of 219 NTZ-PML cases were analyzed, and 184 (84%) underwent PLEX, which did not reduce the mortality risk or the likelihood of poor vs favorable outcomes. Country was predictive of mortality and poor outcome, while PML-IRIS development was predictive of poor outcome.Conclusions: PLEX did not improve the survival or clinical outcomes of Italian or international patients with MS and NTZ-PML, suggesting that this treatment should be performed cautiously in the future. Classification of evidence: This study provides Class III evidence that for patients with NTZ-PML, PLEX does not improve survival. The study lacks the statistical precision to exclude an important benefit or harm of PLEX.

Published
2017

84. Analysis of impact damage and residual static strength in improved CFRP

Author

Clerico, M., Ruvinetti, G., Cipri, F., and Pelosi, M.

Subjects
Non-destructive testing -- Usage, Engineering and manufacturing industries
Abstract

Byline: M. Clerico, G. Ruvinetti, F. Cipri, M. Pelosi Although reinforced plastics are more and more used for structures of aircraft, spacecraft and other vehicles for transportation which could be easily impacted during manufacturing and use, impact damage is expected to greatly reduce the load-carrying capacity of these materials. This paper reports the results of two different sets of falling weight impact experiments performed on 'old' and improved thermosetting carbon fibre composites for obtaining residual tensile and compressive strength, respectively. Impact damage was observed with NDT techniques. During the strength tests acoustic emission was monitored. Tensile tests were specially made for analysing the instrumented impact tester results and NDT for finding slight impact damage. Compressive tests gave the material with the best behaviour after impact.

Published
2010

85. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study

Author

De Marinis, Filippo, Ardizzoni, Andrea, Fontanini, Gabriella, Grossi, Francesco, Cappuzzo, Federico, Novello, Silvia, Santo, Antonio, Lorusso, Vito, Cortinovis, Diego, Iurlaro, Monica, Galetta, Domenico, Gridelli, Cesare, Pedrazzoli P, Siena S, Alabiso O, Bilancia D, Cinieri S, Cartenì G, Fasola G, Ferraù F, Milella M, Contu A, Giuffrida D, Illiano A, Ravaioli A, Zaniboni A, Bettini A, Caprioli A, Longo F, Cruciani G, Defraia E, Favaretto A, Amadori D, Clerico M, Di Costanzo F, Gamucci T, Caruso M, Iacobelli S, Pinotti G, Pozzessere D, Maiello E, Marchetti P, Passalacqua R, Pavesi L, Tortora G, Aglietta M, Brandes A, Ciuffreda L, Daniele B, Demichelis C, Romito S, Tamberi S, Barni S, Barbieri F, Giordano M, Bracarda S, Crinò L, Marzano N, Merlano M, Numico G., BIANCO, ROBERTO, De Marinis, Filippo, Ardizzoni, Andrea, Fontanini, Gabriella, Grossi, Francesco, Cappuzzo, Federico, Novello, Silvia, Santo, Antonio, Lorusso, Vito, Cortinovis, Diego, Iurlaro, Monica, Galetta, Domenico, Gridelli, Cesare, Pedrazzoli, P, Siena, S, Alabiso, O, Bilancia, D, Cinieri, S, Cartenì, G, Fasola, G, Ferraù, F, Milella, M, Contu, A, Giuffrida, D, Illiano, A, Ravaioli, A, Zaniboni, A, Bettini, A, Caprioli, A, Longo, F, Cruciani, G, Defraia, E, Favaretto, A, Amadori, D, Clerico, M, Di Costanzo, F, Gamucci, T, Caruso, M, Iacobelli, S, Pinotti, G, Pozzessere, D, Maiello, E, Marchetti, P, Passalacqua, R, Pavesi, L, Tortora, G, Aglietta, M, Bianco, Roberto, Brandes, A, Ciuffreda, L, Daniele, B, Demichelis, C, Romito, S, Tamberi, S, Barni, S, Barbieri, F, Giordano, M, Bracarda, S, Crinò, L, Marzano, N, Merlano, M, and Numico, G.

Subjects
Oncology, Male, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Longitudinal Studie, medicine.disease_cause, NSCLC, Antineoplastic Agent, Chemotherapy, EGFR, Erlotinib, Third-line, Cohort Studies, Carcinoma, Non-Small-Cell Lung, 80 and over, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Longitudinal Studies, Non-Small-Cell Lung, DOCETAXEL, Aged, 80 and over, Proto-Oncogene Protein, Tumor, CHEMOTHERAPY, Middle Aged, OPEN-LABEL, Receptor Protein-Tyrosine Kinase, ErbB Receptors, Italy, Cohort, Disease Progression, Female, KRAS, CLINICAL-PRACTICE GUIDELINES, medicine.drug, Human, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, ERLOTINIB, Antineoplastic Agents, Proto-Oncogene Proteins p21(ras), Erlotinib Hydrochloride, Internal medicine, Proto-Oncogene Proteins, medicine, Biomarkers, Tumor, Humans, Lung cancer, Aged, III TRIAL, business.industry, Carcinoma, Quinazoline, 3RD-LINE THERAPY, Receptor Protein-Tyrosine Kinases, medicine.disease, ras Protein, 1ST-LINE TREATMENT, FOLLOW-UP, Clinical trial, Lung Neoplasm, Mutation, Quinazolines, ras Proteins, Observational study, Receptor, Epidermal Growth Factor, Cohort Studie, business, Biomarkers
Abstract

Introduction/Background Patients with advanced NSCLC who experience disease progression after second-line therapy might receive further active treatment. LIFE was an Italian cohort multicenter observational study composed of a cross-sectional and a longitudinal phase. Patients and Methods In the longitudinal phase, described here, the primary aim was to determine the proportion of patients receiving third-line therapy among those who received second-line active treatment according to clinical practice. The proportion of patients receiving further treatment lines was also estimated. Results The longitudinal phase was conducted between January and August 2012. Of 464 patients who began second-line therapy outside of clinical trials within the baseline evaluation, 56 (12.1%) were still receiving second-line therapy at the end of the observation period and 17 (3.7%) withdrew during or after second-line therapy. Of the remaining 391 patients, 158 (40.4%) received third-line treatment outside of clinical trials: 93 received a third-line chemotherapy and 65 a targeted agent. The main reason for interrupting third-line treatment was disease progression or death. During the same observation period, 25 of 113 patients who completed a third-line therapy received a fourth line of treatment. From diagnosis of NSCLC to the end of observation, biomarkers were tested in 323 patients (59.7%): epidermal growth factor receptor mutations in 315 (58.2%), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations in 83 (15.3%) and Anaplastic lymphoma kinase (ALK) translocation in 84 (15.5%). Conclusion In Italian clinical practice, the proportion of patients with advanced NSCLC receiving more than 2 treatment lines of therapy is not negligible.

Published
2014

86. Th22 cells are expanded in multiple sclerosisand are resistant to IFN-alpha

Author

Rolla, S, Bardina, V, De Mercanti, S, Quaglino, P, DE PALMA, Raffaele, Gned, D, Brusa, D, Durelli, L, Novelli, F, Clerico, M., Rolla, S, Bardina, V, De Mercanti, S, Quaglino, P, DE PALMA, Raffaele, Gned, D, Brusa, D, Durelli, L, Novelli, F, and Clerico, M.

Subjects
Multiple Sclerosis, Interpheron, Multiple Sclerosi, T cells, T cell
Published
2014

87. TREATMENT CHOICE AFTER 24 NATALIZUMAB DOSES IN PATIENTS WITH MULTIPLE SCLEROSIS: A PROSPECTIVE OBSERVATIONAL STUDY, THE TY-STOP

Author

CLERICO, M, DE MERCANTI, S, PIAZZA, F, GNED, D, DURELLI, L, SCHIAVETTI, L, SORMANI, M, GHEZZI, A, BIANCHI, A, BARONCINI, D, LANZILLO, R, VACCHIANO, L, AMATO, L, BRESCIA MORRA, V, QUARANTELLI, G, SOLA, P, VITETTA, F, FERRARO, D, SIMONE, A, PINESSI, L, CAVALLA, P, SUPERTI, G, FERRÒ, M, D’ONGHIA, M, PAOLICELLI, D, TROJANO M., SALEMI, Giuseppe, REALMUTO, Sabrina, RAGONESE, Paolo, MAZZOLA, Maria Antonietta, CLERICO, M, DE MERCANTI, S, PIAZZA, F, GNED, D, DURELLI, L, SCHIAVETTI, L, SORMANI, M, GHEZZI, A, BIANCHI, A, BARONCINI, D, LANZILLO, R, VACCHIANO, L, AMATO, L, BRESCIA MORRA, V, QUARANTELLI, G, SALEMI, G, REALMUTO, S, RAGONESE, P, MAZZOLA, MA, SOLA, P, VITETTA, F, FERRARO, D, SIMONE, A, PINESSI, L, CAVALLA, P, SUPERTI, G, FERRÒ, M, D’ONGHIA, M, PAOLICELLI, D, and TROJANO M.

Subjects
Multiple scleorsi, natalizumab, Settore MED/26 - Neurologia
Published
2014

89. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis

Author

Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G., Tortorella, C., Simone, I., Patti, F., Ghezzi, A., Zipoli, V., Rossi, P., Pozzilli, C., Salemi, G., Lugaresi, A., Bergamaschi, R., Millefiorini, E., Clerico, M., Lus, G., Vianello, M., Avolio, C., Cavalla, P., Lepore, V., Livrea, P., Comi, G., Amato, M., Di Monte, E., Iaffaldano, P., Direnzo, V., D'Onghia, M., Lo Fermo, S., Messina, S., D'Amico, E., Rizzo, A., Zaffaroni, M., Portaccio, E., Martinelli, V., Prosperini, L., Onesti, E., Aridon, P., D'Amelio, M., Ragonese, P., De Luca, G., Farina, D., Di Tommaso, V., Tavazzi, E., Bargiggia, V., Crivelli, P., Cortese, A., Di Rezze, S., Durastanti, V., Alfieri, G., Rosellini, I., Modesto, M., Notariello, M., Tortorella, P., Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP, Di Monte E, Iaffaldano P, Direnzo V, D'Onghia M, Lo Fermo S, Messina S, D'Amico E, Rizzo A, Zaffaroni M, Portaccio E, Martinelli V, Prosperini L, Onesti E, Aridon P, D'Amelio M, Ragonese P, De Luca G, Farina D, Di Tommaso V, Tavazzi E, Bargiggia V, Crivelli P, Cortese A, Di Rezze S, Durastanti V, Alfieri G, Rosellini I, Modesto M, Notariello M, Tortorella P, Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Zipoli, V, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, Alessandra, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Lepore, V, Livrea, P, Comi, G, and Amato, Mp

Subjects
Adult, Male, Time Factors, Multiple Sclerosis, Interferon beta, Interferon-beta, Cohort Studies, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Treatment Outcome, observational study, multiple sclerosis, interferon, treatment, early, Sickness Impact Profile, Multiple Sclerosi, Quality of Life, Humans, Female, Settore MED/26 - Neurologia, Prospective Studies, Follow-Up Studies
Abstract

OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. delayed IFNbeta treatment on risk of reaching a 1-point progression in the Expanded Disability Status Scale (EDSS) score, and the EDSS 4.0 and 6.0 milestones. A set of PS-adjusted Cox hazards regression models were calculated according to different times of treatment initiation (within 1 year up to within 5 years from disease onset). A sensitivity analysis was performed to assess the robustness of findings. RESULTS: The lowest hazard ratios (HRs) for the three PS quintiles-adjusted models were obtained by a cutoff of treatment initiation within 1 year from disease onset. Early treatment significantly reduced the risk of reaching a 1-point progression in EDSS score (HR = 0.63; 95% CI = 0.48-0.85; p < 0.002), and the EDSS 4.0 milestone (HR = 0.56; 95% CI = 0.36-0.90; p = 0.015). Sensitivity analysis showed the bound of significance for unmeasured confounders. INTERPRETATION: Greater benefits on disability progression may be obtained by an early IFNbeta treatment in RRMS.

Published
2009

90. Abstract PD6-04: HOHO study: How European and US young women cope with breast cancer and fertility concerns

Author

Pagani, O, primary, Bagnardi, V, additional, Ruggeri, M, additional, Bianco, N, additional, Gallerani, E, additional, Buser, K, additional, Giordano, M, additional, Gianni, L, additional, Rabaglio, M, additional, Freschi, A, additional, Cretella, E, additional, Clerico, M, additional, Amadori, D, additional, Simoncini, E, additional, Ciccarese, M, additional, Rauch, D, additional, Glaus, A, additional, Berardi, R, additional, Franzetti, A, additional, Ruddy, KJ, additional, Gelber, S, additional, Partridge, AH, additional, and Colleoni, M, additional

Published
2017
Full Text
View/download PDF

91. Discontinuation of treatment with Natalizumab after 24 courses. Report from spontaneous, observational, prospective study (TYSTOP)

Author

Clerico, M, De Mercanti, S, Piazza, F, Versino, E, Gned, D, Gibbin, M, Brescia Morra, V, Lanzillo, R, Amato, L, Quarantelli, M, Ghezzi, A, Bianchi, A, Baroncini, D, Ferrò, MT, Vitetta, F, D’Onghia, M, Paolicelli, D, Trojano, M, Durelli L., SALEMI, Giuseppe, REALMUTO, Sabrina, Clerico, M, De Mercanti, S, Piazza, F, Versino, E, Gned, D, Gibbin, M, Brescia Morra, V, Lanzillo, R, Amato, L, Quarantelli, M, Ghezzi, A, Bianchi, A, Baroncini, D, Salemi, G, Realmuto, S, Ferrò, MT, Vitetta, F, D’Onghia, M, Paolicelli, D, Trojano, M, and Durelli L

Subjects
Multiple Sclerosis, Natalizumab, TySTOP, Settore MED/26 - Neurologia
Published
2013

96. post marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in intereron beta treatment

Author

TROJANO M, PELLEGRINI F, PAOLICELLI D, FUIANI A, ZIMATORE GB, TORTORELLA C, SIMONE IL, PATTI F, GHEZZI A, PORTACCIO E, ROSSI P, POZZILLI C, SALEMI G, LUGARESI A, BERGAMASCHI R, MILLEFIORINI E, CLERICO M, LUS G, VIANELLO M, AVOLIO C, CAVALLA P, IAFFALDANO P, DIRENZO V, D'ONGHIA M, LEPORE V, LIVREA P, AMATO MP, ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK GROUP, COMI , GIANCARLO, Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Portaccio, E, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Iaffaldano, P, Direnzo, V, D'Onghia, M, Lepore, V, Livrea, P, Comi, Giancarlo, Amato, Mp, and ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK, Group

Published
2009

98. Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b

Author

Durelli, L, Ricci, A, Barbero, P, Cucci, A, Ferrero, B, Festa, E, Contessa, G, De Mercanti, S, Ripellino, P, Lapuma, D, Viglietta, E, Ferrero, C, Bergui, M, Versino, E, Clerico, M, Rottoli, M, Moroni, S, Teatini, F, Schoenhuber, R, Spissu, A, Reggio, A, Lo Fermo S, Liberto, A, Perla, F, Grasso, E, Montanari, E, Pesci, I, Manneschi, L, Grezzi, A, Zaffaroni, M, Carolei, A, Totaro, R, Giuliani, G, Pucci, E, Cartechini, E, Scarpini, E, Clerici, R, Protti, A, Erminio, C, Cotrufo, R, Lus, G, Bergamaschi, R, Romani, A, Iudice, A, Frittelli, C, Motti, L, Marcello, N, Meola, G, Robotti, M, Cavallo, R, Ravetti, C, Deotto, L., SAVETTIERI, Giovanni, SALEMI, Giuseppe, Durelli, L, Ricci, A, Barbero, P, Cucci, A, Ferrero, B, Festa, E, Contessa, G, De Mercanti, S, Ripellino, P, Lapuma, D, Viglietta, E, Ferrero, C, Bergui, M, Versino, E, Clerico, M, Rottoli, M, Moroni, S, Teatini, F, Schoenhuber, R, Spissu, A, Reggio, A, Lo Fermo S, Liberto, A, Perla, F, Grasso, E, Montanari, E, Pesci, I, Manneschi, L, Grezzi, A, Zaffaroni, M, Carolei, A, Totaro, R, Giuliani, G, Pucci, E, Cartechini, E, Scarpini, E, Clerici, R, Protti, A, Erminio, C, Cotrufo, R, Lus, G, Savettieri, G, Salemi, G, Bergamaschi, R, Romani, A, Iudice, A, Frittelli, C, Motti, L, Marcello, N, Meola, G, Robotti, M, Cavallo, R, Ravetti, C, and Deotto, L

Subjects
Multiple sclerosis, interferon-beta-1b, Settore MED/26 - Neurologia
Published
2009

99. rel-life impact of early interferon beta therapy in relapsing multiple sclerosis

Author

TROJANO M, PELLEGRINI F, PAOLICELLI D, FUIANI A, ZIMATORE GB, TORTORELLA C, SIMONE IL, PATTI F, GHEZZI A, ZIPOLI V, ROSSI P, POZZILLI C, SALEMI G, LUGARESI A, BERGAMASCHI R, MILLEFIORINI E, CLERICO M, LUS G, VIANELLO M, AVOLIO C, CAVALLA P, LEPORE V, LIVREA P, AMATO MP, ITALIAN MULTIPLE SCLEROISS DATABASE NETWORK MSDN GROUP, COMI , GIANCARLO, Trojano, M, Pellegrini, F, Paolicelli, D, Fuiani, A, Zimatore, Gb, Tortorella, C, Simone, Il, Patti, F, Ghezzi, A, Zipoli, V, Rossi, P, Pozzilli, C, Salemi, G, Lugaresi, A, Bergamaschi, R, Millefiorini, E, Clerico, M, Lus, G, Vianello, M, Avolio, C, Cavalla, P, Lepore, V, Livrea, P, Comi, Giancarlo, Amato, Mp, and ITALIAN MULTIPLE SCLEROISS DATABASE NETWORK MSDN, Group

Published
2009

100. Breast cancer 'tailored follow-up' in Italian oncology units: a web-based survey

Author

Natoli, C., Brocco, D., Sperduti, I., Nuzzo, A., Tinari, N., De Tursi, M., Grassadonia, A., Mazzilli, L., Iacobelli, S., Gamucci, T., Vici, P., Study, Group, Adamo, V., Airoldi, M., Amoroso, D., Angelini, F., Angiolini, C., Angiolucci, G., Ardizzoia, A., Baldini, E., Ballardini, P., Barni, S., Barone, C., Battelli, N., Bernardi, D., Bianchetti, S., Bianco, N., Biglia, Nicoletta, Bilancia, D., Biti, G., Boni, C., Bordonaro, R., Botta, M., Bretti, S., Brunello, A., Brunetti, C., Bruno, D., Bucci, E., Buzzoni, R., Cagossi, K., Cappelletti, C., Cappuzzo, F., Cardillo, F., Carroccio, R., Cascinu, S., Cavanna, L., Cianchetti, E., Clerico, M., Contu, A., Corsi, D., Cortesi, L., Cretella, E., Crispino, S., Di Lieto, M., Di Lullo, L., Durini, E., Fabi, A., Failla, G., Fattorusso, S., Ferraù, F., Ferro, A., Ficorella, C., Fogazzi, G., Foglietta, J., Francini, G., Fusco, O., Gennari, A., Ghiani, M., Gianni, L., Giordano, M., Giotta, F., Giuliani, R., Gori, S., Graiff, C., Guarneri, V., Guarneri, D., Guglielmi, F., Landriscina, M., Laudadio, L., Lombardo, M., Longo, F., Macellari, G., Madeddu, C., Magnanini, S., Maiorino, L., Mangiameli, A., Marini, G., Massidda, B., Mattioli, R., Michelotti, A., Molino, A., Montesarchio, V., Morale, A., Murgo, R., Naso, G., Natale, D., Orditura, M., Orrù, S., Pace, R., Palazzo, A., Palma, F., Pancotti, A., Pandoli, G., Papaldo, P., Parisi, A. M., Passalacqua, R., Pellegrino, A., Perrucci, B., Proietti, E., Recchia, F., Riccardi, F., Rispoli, A. I., Rocca, A., Romaniello, I., Rossetti, R., Rossi, D., Rosti, G., Ruggeri, E. M., Russo, A., Savarino, A., Savastano, C., Scognamiglio, G., Scognamiglio, M., Seminara, P., Serrachini, S., Sidoti, V., Silva, R. R., Surace, G., Tomao, S., Tonini, G., Trenta, P., Turazza, M., Valenza, R., Veltri, E., Zampa, G., Zaniboni, A., Zanirato, S., C, Natoli, D, Brocco, I, Sperduti, A, Nuzzo, N, Tinari, M, De Tursi, A, Grassadonia, L, Mazzilli, S, Iacobelli, T, Gamucci, P, Vici, Study Group, 'FOLLOW-UP', and Orditura, Michele

Subjects
Oncology, breast cancer, Follow-up, survey, Medical Oncology, law.invention, Randomized controlled trial, law, Aged, Breast Neoplasms, Female, Follow-Up Studies, Health Care Surveys, Humans, Italy, Middle Aged, Secondary Prevention, Guideline Adherence, Breast Tumors, Medicine and Health Sciences, Web based survey, Multidisciplinary, Pharmaceutics, Surgical Oncology, Cancer Therapy, Medicine, medicine.symptom, Disease staging, Research Article, medicine.medical_specialty, Adjuvant Cancer Chemotherapy, Science, MEDLINE, Asymptomatic, Breast cancer, Drug Therapy, Internal medicine, medicine, Cancer Detection and Diagnosis, Chemotherapy, Modalities, business.industry, Cancers and Neoplasms, medicine.disease, Blood chemistry, Women's Health, Clinical Medicine, business
Abstract

PurposeBreast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice.MethodsReferents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year.ResultsBetween February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years.ConclusionsOur survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called "tailored follow-up", high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results